AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas

Modesto Morganelli
Novembre 20, 2020

Competition has intensified among pharmaceutical companies racing to develop a Covid-19 shot, with two vaccines - one by United States company Pfizer and its German partner BioNTech, and another by U.S. firm Moderna - publishing large-scale trial data this month that showed their jabs were around 95 percent effective against Covid-19. The human body can become immune to the adenoviral vectors used in the vaccine, which makes booster shots more hard.

The findings show the vaccine creates as strong an immune response in those over age 70 as it does in younger adults. Studies with nonhuman primates found that a single dose of the vaccine generates humoral and cellular immune responses and protects the lower respiratory tract from infection.

An independent panel will decide when the results are ready, and they are waiting to see 53 cases of coronavirus in the trial population before "unblinding" the study.

Within each of these groups, participants were randomised to receive either the Oxford vaccine, or a control vaccine (the meningococcal conjugate vaccine) which wouldn't provide protection against SARS-CoV-2.

From the earlier phase data, researchers found that younger participants experienced side effects like pain at the vaccine's injection site, fever and muscle ache more often than older adults.

Study recruitment occurred during a national lockdown in the United Kingdom when vulnerable individuals were advised to self-isolate. Participants will continue to be followed for one year following final vaccination.

In the randomized, double-blind, placebo-controlled phase 1 and 2 clinical trials, the researchers enrolled healthy adults between 18 and 59 years old in Suining County of Jiangsu province, China. The incidence of adverse reactions in the 3 micrograms and 6 microgram groups were similar.

A coronavirus vaccine created by a collaboration between drugmaker AstraZeneca and the University of Oxford is showing results that it is safe and triggers a similar immune response among adults of all ages, according to preliminary results of their phase 2 study. It is also generating a good antibody response.

"The robust antibody and T-cell responses seen in older people in our study are encouraging", added co-author, Dr. Maheshi Ramasamy, PhD, from the University of Oxford.

Older adults have been shown to be at higher risk from COVID-19 and should be considered to be a priority for immunisation should any effective vaccine be developed for the disease. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure". Both vaccines have yet to be approved by Health Canada.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE